Arsenal buys GHO's Caprion Biosciences, will merge with HistoGeneX
U.K. healthcare private equity firm GHO Capital Partners has sold Caprion Biosciences, a Montréal-based provider of immunology and proteomics services to the biopharmaceutical industry. No financial terms were disclosed. The buyer was Arsenal Capital Partners, a U.S. healthcare and specialty industrials private equity firm. In a separate release, Arsenal said it will invest in Caprion's merger with Antwerp, Belgium-based HistoGeneX, creating a single provider of research services for the development of immunology- and oncology-focused drugs. HistoGeneX was formerly backed by Waterland Private Equity Investments. Founded in 2000, Caprion was acquired and recapitalized in 2016 by GHO.
31 July 2019•4 mins read
